PMC3747451_01
Carcinoid neuroendocrine tumor, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis.
CRIM.HEMATOLOGY2013-391086.001.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.001.jpg
fig1
The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with atrophic gastritis (Figures 1 and 2).
Carcinoid neuroendocrine tumor, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis.
CRIM.HEMATOLOGY2013-391086.002.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.002.jpg
fig2
The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with atrophic gastritis (Figures 1 and 2).
Immunohistochemistry exam positive for chromogranin A.
CRIM.HEMATOLOGY2013-391086.003.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.003.jpg
fig3
The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
Immunohistochemistry exam positive for synaptophysin.
CRIM.HEMATOLOGY2013-391086.004.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.004.jpg
fig4
The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
Immunohistochemistry exam positive for CD56.
CRIM.HEMATOLOGY2013-391086.005.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.005.jpg
fig5
The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
Platelet count after initiation of octreotide treatment.
CRIM.HEMATOLOGY2013-391086.006.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.006.jpg
fig6
Immediately after the first doses of octreotide, a constant increase in the platelet count was evidenced in the CBC, reaching 109,000 platelets/mm3 (Figure 6).
Platelet count after discontinuation of octreotide.
CRIM.HEMATOLOGY2013-391086.007.jpg
PMC3747451_01_CRIM.HEMATOLOGY2013-391086.007.jpg
fig7